SCHEMBL26568178

SCHEMBL26568178

COC(=O)CNC(=O)c1ccc(-c2ccc(F)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.59
MAPK1 P28482 1/20 0.55
KDM4E B2RXH2 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 1/20 0.54
TSHR P16473 1/20 0.54
HSD17B10 Q99714 1/20 0.54
ALDH1A1 P00352 4/20 0.53
HPGD P15428 1/20 0.53
PTPN1 P18031 1/20 0.51
GAA P10253 1/20 0.51
SLC6A9 P48067 2/20 0.51
SLC6A5 Q9Y345 2/20 0.51
MAPT P10636 1/20 0.51
RAB9A P51151 1/20 0.51
MCHR1 Q99705 1/20 0.50
LMNA P02545 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
EPHX2 P34913 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19472394 0.95 KMT2A (0.63) KMT2AKDM4ESMN1; SMN2MEN1TSHR
SCHEMBL8947242 0.86 KMT2A (0.67) KMT2AMAPK1KDM4ESMN1; SMN2MEN1
SCHEMBL26579684 0.86 MAPK1 (0.76) KMT2AMAPK1KDM4ESMN1; SMN2MEN1
SCHEMBL5632141 0.85 RAB9A (0.67) KMT2AMAPK1KDM4ESMN1; SMN2MEN1
SCHEMBL16495499 0.83 RXFP1 (0.56) KMT2AKDM4ESMN1; SMN2MEN1TSHR
SCHEMBL26566648 0.81 KDM4E (0.61) KDM4ESMN1; SMN2ALDH1A1HPGDPTPN1
Methylene Chloride SCHEMBL6847437 0.81 RAB9A (0.62) KMT2AMAPK1KDM4ESMN1; SMN2MEN1
SCHEMBL23099698 0.81 NPC1 (0.67) KMT2AKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL8718154 0.80 EGLN1 (0.64) KMT2AMAPK1KDM4ESMN1; SMN2MEN1
SCHEMBL14723435 0.80 PTPN1 (0.58) ALDH1A1HPGDPTPN1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed